Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study.
暂无分享,去创建一个
D. Vail | I. Kurzman | X. Pan | K. Tsimbas
[1] M. Pennell,et al. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose , 2013, BMC Veterinary Research.
[2] D. Thamm,et al. Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours. , 2012, Veterinary and comparative oncology.
[3] D. Vail,et al. Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study. , 2012, Veterinary and comparative oncology.
[4] C. London,et al. Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study. , 2012, Veterinary and comparative oncology.
[5] C. Rodriguez,et al. Prospective randomized clinical trial assessing the efficacy of Denamarin for prevention of CCNU-induced hepatopathy in tumor-bearing dogs. , 2011, Journal of veterinary internal medicine.
[6] N. Northrup,et al. Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma. , 2010, Journal of veterinary internal medicine.
[7] D. Russell,et al. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours. , 2010, Veterinary and comparative oncology.
[8] J. Boucher,et al. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors. , 2010, Journal of veterinary pharmacology and therapeutics.
[9] S. Marsh,et al. Distribution, metabolism, and excretion of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in dogs. , 2010, Journal of veterinary pharmacology and therapeutics.
[10] C. Khanna,et al. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)--a Veterinary Cooperative Oncology Group (VCOG) consensus document. , 2010, Veterinary and comparative oncology.
[11] J. Schlessinger,et al. Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.
[12] F. Millanta,et al. Expression of vascular endothelial growth factor in canine inflammatory and non-inflammatory mammary carcinoma. , 2010, Journal of comparative pathology.
[13] D. Haines,et al. Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor in canine cutaneous fibrosarcomas. , 2009, Journal of comparative pathology.
[14] D. Malarkey,et al. Expression of epidermal growth factor receptor and vascular endothelial growth factor in malignant canine epithelial nasal tumours. , 2009, Veterinary and comparative oncology.
[15] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[16] D. Haines,et al. Immunohistochemical Expression of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Associated with Tumor Cell Proliferation in Canine Cutaneous Squamous Cell Carcinomas and Trichoepitheliomas , 2007, Veterinary pathology.
[17] D. Vail. Cancer clinical trials: development and implementation. , 2007, The Veterinary clinics of North America. Small animal practice.
[18] G. Scagliotti. Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] W. Pickl,et al. Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. , 2007, Veterinary immunology and immunopathology.
[20] D. Thamm,et al. Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma. , 2007, Journal of veterinary internal medicine.
[21] F. Millanta,et al. The role of vascular endothelial growth factor and its receptor Flk-1/KDR in promoting tumour angiogenesis in feline and canine mammary carcinomas: a preliminary study of autocrine and paracrine loops. , 2006, Research in veterinary science.
[22] P. Bergman,et al. Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): a retrospective study of 46 cases (1999-2004). , 2006, Journal of veterinary internal medicine.
[23] H. Sakai,et al. Expression of Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor, and Their Receptors (Flt-1, Flk-1, and Flg-1) in Canine Vascular Tumors , 2006, Veterinary pathology.
[24] J. Pujol,et al. Gefitinib (IRESSA) with Vinorelbine or Vinorelbine/Cisplatin for Chemotherapy-Naive Non-small Cell Lung Cancer Patients , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[25] S. Platt,et al. Vascular endothelial growth factor expression in canine intracranial meningiomas and association with patient survival. , 2006, Journal of veterinary internal medicine.
[26] J. Sur,et al. Long-term chemotherapy with lomustine of intracranial meningioma occurring in a miniature schnauzer. , 2006, The Journal of veterinary medical science.
[27] S. Lana,et al. CCNU in the treatment of canine epitheliotropic lymphoma. , 2006, Journal of veterinary internal medicine.
[28] N. Shenoy,et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] N. Shenoy,et al. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. , 2002, Blood.
[30] G. De Vico,et al. Expression of Vascular Endothelial Growth Factor in Canine Mammary Tumors , 2002, Veterinary pathology.
[31] G. De Vico,et al. Expression of vascular endothelial growth factor in basal cell tumours and in squamous cell carcinomas of canine skin. , 2000, Journal of comparative pathology.
[32] D. Waxman,et al. 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) modulates rat liver microsomal cyclophosphamide and ifosphamide activation by suppressing cytochrome P450 2C11 messenger RNA levels. , 1994, Drug metabolism and disposition: the biological fate of chemicals.